Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study

Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis. Japanese patients aged 20 years or more with moderate to severe plaque psoriasis and/or psoriatic arthritis were double‐blindly randomized 1:1 to tofacitinib 5 or 10 mg b.i.d. for 16 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales: Asahina, Akihiko, Etoh, Takafumi, Igarashi, Atsuyuki, Imafuku, Shinichi, Saeki, Hidehisa, Shibasaki, Yoshiyuki, Tomochika, Yukiko, Toyoizumi, Shigeyuki, Nagaoka, Makoto, Ohtsuki, Mamitaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067558/
https://www.ncbi.nlm.nih.gov/pubmed/26875540
http://dx.doi.org/10.1111/1346-8138.13258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067558/
https://www.ncbi.nlm.nih.gov/pubmed/26875540
http://dx.doi.org/10.1111/1346-8138.13258

Ejemplares similares